HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays

doi:10.3748/wjg.v19.i38.6438

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6890)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

490

HTML

3761

Figures (1-4)

276

Tables (1-6)

307

Sum=4834

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1163

Download

893

Sum=2056

Oct 14, 2013 (publication date) through Dec 19, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 14, 2013; 19(38): 6438-6446
Published online Oct 14, 2013. doi: 10.3748/wjg.v19.i38.6438

HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays

Lucas Faria Abrahão-Machado, Alexandre Andrade dos Anjos Jácome, Durval Renato Wohnrath, José Sebastião dos Santos, Estela Cristina Carneseca, José Humberto Tavares Guerreiro Fregnani, Cristovam Scapulatempo-Neto

Lucas Faria Abrahão-Machado, Cristovam Scapulatempo-Neto, Department of Pathology, Barretos Cancer Hospital, Barretos, Sao Paulo 14784-400, Brazil

Alexandre Andrade dos Anjos Jácome, Department of Clinical Oncology, Mater Dei Hospital, Belo Horizonte, Minas Gerais 30140-092, Brazil

Durval Renato Wohnrath, Department of Gastrointestinal Surgical Oncology, Barretos Cancer Hospital, Barretos, Sao Paulo 14784-400, Brazil

José Sebastião dos Santos, Department of Surgery and Anatomy, University of São Paulo-Ribeirão Preto School of Medicine, Ribeirão Preto, Sao Paulo 14049-900, Brazil

Estela Cristina Carneseca, Biostatistician at Cancer Registry Department, Barretos Cancer Hospital, Barretos, Sao Paulo 14784-400, Brazil

José Humberto Tavares Guerreiro Fregnani, Researcher Support Center, Barretos Cancer Hospital, Barretos, Sao Paulo 14784-400, Brazil

Author contributions: Abrahão-Machado LF and Scapulatempo-Neto C designed the research; Abrahão-Machado LF, Scapulatempo-Neto C and Jácome AAA performed the research; Carneseca EC and Fregnani JHTG contributed with analytic tools; Abrahão-Machado LF and Scapulatempo-Neto C analyzed the data; Abrahão-Machado LF wrote the paper; Wohnrath DR and Santos JS revised the final version.

Correspondence to: Lucas Faria Abrahão-Machado, MD, Department of Pathology, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331, Barretos, Sao Paulo 14784-400, Brazil. lucasfariamachado@yahoo.com

Telephone: +55-17-3321660-6987 Fax: +55-17-3321660-7117

Received: June 5, 2013
Revised: July 12, 2013
Accepted: July 17, 2013
Published online: October 14, 2013
Processing time: 131 Days and 19.5 Hours

Core Tip

Core tip: This is the first study to compare the three widely used anti-human epidermalgrowth factor receptor 2 (HER2) antibodies 4B5, SP3 and HercepTest in tissue microarrays and whole-tissue sections prepared from paraffin blocks of a single series of gastric tumors. We aimed to find the best method to assess HER2 expression in gastric cancer, facilitating the choice of the antibody with the greatest ability to identify the most patients who could benefit from the use of trastuzumab. Besides, we demonstrated that HER2 expression in small samples of gastric cancer (such as tissue microarrays and biopsies) should be evaluated cautiously because these tumors exhibit intratumoral heterogeneity that may influence the results.